Alector Q4 net loss widens to $37.3 mln

Alector

25/02/2026 21:36

Overview

Biotech firm's Q4 revenue fell yr/yr due to completed performance obligations

Net loss for Q4 widened to $37.3 mln from $2.1 mln yr/yr

Company holds $256 mln in cash, funding operations through 2027

Outlook

Alector expects interim futility analysis for PROGRESS-AD trial in 1H 2026

Company plans IND application for AL137 in late 2026 or early 2027

Alector's cash position expected to fund operations through 2027

Result Drivers

Cash, cash equivalents, and investments were $256.0 million as of December 31, 2025

Total research and development expenses for the quarter ended December 31, 2025, were $32.5 million, compared to $46.5 million for the same period in 2024

Company press release: ID:nGNX7TBdmQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$6.24 mln
Q4 EPS
-$0.34
Q4 Net Income
-$37.27 mln
Q4 Basic EPS
-$0.34


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Alector Inc is $1.25, about 42.9% below its February 24 closing price of $2.19

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)